This post was originally published on this site

A Deadline is coming up on May 3, 2021 in the lawsuit for certain investors in Athenex, Inc. (NASDAQ: ATNX).

A deadline is coming up on May 3, 2021 in the lawsuit filed for certain investors of Athenex, Inc. (NASDAQ: ATNX) over alleged securities laws violations by Athenex, Inc.

Investors who purchased shares of Athenex, Inc. (NASDAQ: ATNX) have certain options and there are strict and short deadlines running. Deadline: May 3, 2021. NASDAQ: ATNX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

According to the complaint filed in the U.S. District Court for the Western District of New York the plaintiff alleges on behalf of purchasers of Athenex, Inc. (NASDAQ: ATNX) common shares between August 7, 2019 and February 26, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 7, 2019 and February 26, 2021, the Defendants failed to disclose to investors that the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae, that the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR, that the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR, that the Company’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial, that as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form, and that as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of Athenex, Inc. (NASDAQ: ATNX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.